StockData
IN8bio, Inc. logo

IN8bio, Inc. (INAB) company profile

INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.82+0.00 (+0.49%)

Close on Nov 17, 2026Market cap $8.08MP/E –Yield –

About IN8bio

Biological Products, (No Diagnostic Substances), SIC 2836

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers. The company develops ex vivo expanded, activated, and genetically engineered gamma-delta T cell therapies using its DeltEx platform to treat cancer and autoimmune diseases. Its therapeutic programs evaluate allogeneic, autologous, and stem-cell-derived approaches, as well as T cell engagers designed to selectively direct gamma-delta T cells against target cells. The company does not currently have commercial products and develops its treatments to serve patients suffering from hematologic cancers, solid tumors, and autoimmune conditions.

The company operates clinical and preclinical development programs within the United States. Its lead cellular therapy candidates undergo evaluation across multiple American medical centers, including the Kansas University Cancer Center and The Ohio State University. IN8bio maintains its principal executive offices in New York, New York.

Summary of the business section of IN8bio's latest annual report, written by StockData.

Company profile

Company

Legal name
IN8bio, Inc.
Headquarters
New York, NY
Address
Empire State Building, 350 5th Avenue, Suite 5330 10118
Phone
(646) 600-6438
Website
in8bio.com
Employees
17, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
CohnReznick LLP, New York, New York

Stock & identifiers

Ticker
INAB
Exchange
Nasdaq
IPO date
Jul 30, 2021
Shares outstanding
10M, Aug 3, 2026
Public float
$7.60M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-30 reverse, Jun 6, 2025
SEC CIK
1740279
CUSIP
45674E208
ISIN
US45674E2081
FIGI
BBG00XX9K1M2
Share class FIGI
BBG00XX9K2G7
LEI
549300H68IVCRKSGSL94
EIN
82-5462585

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
William Tai-Wei HoCEO, Director124,817
Kate RochlinPresident and COO9,085
Patrick McCallCHIEF FINANCIAL OFFICER9,482
Lawrence LambEVP and CSO101,369
Emily FairbairnDirector0
Luba GreenwoodDirector7,826
Peter C. BrandtDirector98,690
Jeremy R. GraffDirector4,549
Corinne EpperlyDirector81,967
Alan S. RoemerDirector49,514
Travis WhitfillDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
William Ho
Chief Executive Officer
$397.80K$210.32K$336.60K$9.00K$953.72K-34%
Kate Rochlin, Ph.D.
President and Chief Operating Officer
$417.87K$78.13K$192.85K–$688.85K-13%
Patrick McCall
Chief Financial Officer
$404.95K$79.06K$184.18K$9.00K$677.20K-13%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 30, 2021
Offer price
$10.00
Securities offered
4,000,000
Gross proceeds
$40.00M
Exchange
Nasdaq
First trading day
Jul 30, 2021
First-day close
$10.00+0.0%
Lock-up ends (est.)
Jan 26, 2022

“The initial public offering price is $10.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 17 full-time employees, of whom 13 were primarily engaged in research and development activities.”

Corporate history

Events identified from SEC filings

DateEventDetails
Feb 7, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 30, 2021IPOInitial public offering priced (424B4 prospectus)
Nov 10, 2020ListingRegistration of securities on an exchange (Form 8-A)
Sep 20, 2018Name changeName changed from Incysus Therapeutics, Inc. to IN8bio, Inc.

See a number that looks wrong?